| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
127,470,000 |
| Market
Cap: |
1.68(B) |
| Last
Volume: |
716,758 |
Avg
Vol: |
1,073,286 |
| 52
Week Range: |
$11.665 - $20.73 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile NeoGenomics operate a network of cancer-focused testing laboratories in the U.S., Europe and Asia. Co.'s testing services include the following: Cytogenetics (karyotype analysis), a study of chromosomes and their relationship to disease; Fluorescence In-Situ Hybridization, a molecular cytogenetic technique that focuses on detecting and localizing the presence or absence of specific DNA sequences and genes on chromosomes; Flow cytometry, a technique utilized to measure the characteristics of cell populations; Immunohistochemistry and Digital Imaging; Molecular testing; and Morphologic analysis, a process of analyzing cells under the microscope.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
1,049 |
9,748 |
12,417 |
12,417 |
| Total Sell Value |
$16,511 |
$152,803 |
$201,886 |
$201,886 |
| Total People Sold |
1 |
2 |
2 |
2 |
| Total Sell Transactions |
1 |
3 |
4 |
4 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hipp Raymond R |
Director |
– • – |
2019-02-26 |
4 |
S |
$18.90 |
$357,002 |
D/D |
(18,889) |
287,580 |
|
- |
|
| Hipp Raymond R |
Director |
– • – |
2019-02-26 |
4 |
OE |
$4.78 |
$122,646 |
D/D |
18,889 |
306,469 |
|
- |
|
| Bonello William |
Chief Strategy Officer |
• – – |
2019-02-26 |
4 |
S |
$18.90 |
$1,137,837 |
D/D |
(60,203) |
0 |
|
- |
|
| Bonello William |
Chief Strategy Officer |
• – – |
2019-02-26 |
4 |
OE |
$7.52 |
$473,211 |
D/D |
60,203 |
60,203 |
|
- |
|
| Johnson Kevin C |
Director |
– • – |
2018-12-21 |
4 |
B |
$11.60 |
$301,600 |
D/D |
26,000 |
103,866 |
2.39 |
- |
|
| Ge Medical Systems Information Technologies, Inc. |
Former 10% Owner |
– – – |
2018-12-14 |
4 |
S |
$12.00 |
$130,021,740 |
I/I |
(10,835,145) |
0 |
|
- |
|
| Tetrault Lynn A. |
Director |
– • – |
2018-11-19 |
4 |
S |
$15.97 |
$207,940 |
D/D |
(13,000) |
38,234 |
|
- |
|
| Tetrault Lynn A. |
Director |
– • – |
2018-11-15 |
4 |
OE |
$6.66 |
$141,437 |
D/D |
18,888 |
56,234 |
|
- |
|
| Tetrault Lynn A. |
Director |
– • – |
2018-11-14 |
4 |
S |
$16.16 |
$80,800 |
D/D |
(5,000) |
51,234 |
|
- |
|
| Jones Steven C |
Executive Vice President |
• • – |
2018-11-14 |
4 |
S |
$16.50 |
$91,625 |
I/I |
(5,553) |
184,271 |
|
- |
|
| Jones Steven C |
Executive Vice President |
• • – |
2018-11-13 |
4 |
S |
$16.66 |
$593,610 |
I/I |
(35,574) |
186,000 |
|
- |
|
| Balliet Jennifer |
VP and Chief Culture Officer |
• – – |
2018-11-13 |
4/A |
A |
$0.00 |
$0 |
D/D |
6,678 |
20,000 |
|
- |
|
| Jones Steven C |
Executive Vice President |
• • – |
2018-11-12 |
4 |
S |
$16.66 |
$1,666,000 |
I/I |
(100,000) |
2,200,000 |
|
- |
|
| Balliet Jennifer |
VP and Chief Culture Officer |
• – – |
2018-11-12 |
4 |
S |
$16.73 |
$476,889 |
D/D |
(28,505) |
20,000 |
|
- |
|
| Shovlin Robert J. |
President, Clinical Services |
• – – |
2018-11-12 |
4 |
S |
$16.76 |
$611,623 |
D/D |
(36,493) |
123,391 |
|
- |
|
| Ge Medical Systems Information Technologies, Inc. |
10% Owner |
– – • |
2018-11-09 |
4 |
S |
$16.75 |
$69,761,321 |
I/I |
(4,164,855) |
10,835,145 |
|
- |
|
| Balliet Jennifer |
VP and Chief Culture Officer |
• – – |
2018-11-09 |
4 |
S |
$17.00 |
$677,076 |
D/D |
(39,828) |
48,505 |
|
- |
|
| Balliet Jennifer |
VP and Chief Culture Officer |
• – – |
2018-11-09 |
4 |
OE |
$0.00 |
$167,300 |
D/D |
68,333 |
88,333 |
|
- |
|
| Johnson Kevin C |
Director |
– • – |
2018-11-09 |
4 |
S |
$17.01 |
$1,124,180 |
D/D |
(66,007) |
77,866 |
|
- |
|
| Shovlin Robert J. |
President, Clinical Services |
• – – |
2018-11-09 |
4 |
S |
$17.05 |
$3,069,000 |
D/D |
(180,000) |
159,884 |
|
- |
|
| Shovlin Robert J. |
President, Clinical Services |
• – – |
2018-11-09 |
4 |
OE |
$4.79 |
$1,437,000 |
D/D |
300,000 |
339,884 |
|
- |
|
| Brodie Steven G. |
VP - Pharma Operations |
• – – |
2018-10-22 |
4 |
OE |
$3.45 |
$46,002 |
D/D |
13,334 |
45,953 |
|
- |
|
| Van Oort Douglas M |
Chairman and CEO |
• • – |
2018-08-03 |
4/A |
A |
$0.00 |
$0 |
D/D |
197,042 |
2,030,027 |
|
- |
|
| Van Oort Douglas M |
Chairman and CEO |
• • – |
2018-08-03 |
4/A |
D |
$0.00 |
$0 |
D/D |
(21,904) |
2,008,123 |
|
- |
|
| Van Oort Douglas M |
Chairman and CEO |
• • – |
2018-08-01 |
4 |
A |
$0.00 |
$0 |
D/D |
46,429 |
2,054,552 |
|
- |
|
431 Records found
|
|
Page 12 of 18 |
|
|
0.24 (1.79%) 
